Table 1.
A summary of the most common imaging-based response criteria used in oncology drug development
| Indication | Criteria | Imaging modalities | Reference |
|---|---|---|---|
| Solid tumours | |||
| Oncology | RECIST 1.1 | CT, MRI, [18F]FDG-PET, X-ray, bone scintigraphy | Eisenhauer et al., 2009 77 |
| ImmunoOncology | irRC (superseded) irRECIST iRECIST | CT, MRI, PET, X-ray, bone scintigraphy | Seymour et al., 2017 80 |
| Oncology | PET Response Criteria in Solid Tumours (PERCIST) | FDG PET, CT | Wahl et al., 2009 81 |
| Intratumoral (IT) | itRECIST | CT, MRI, [18F]FDG-PET, X-ray, bone scintigraphy, photography/caliper. | Goldmacher et al., 2020 82 |
| Gastrointestinal stromal tumour (GIST) | Choi | CT, [18F]FDG-PET | Choi et al., 2007 83 |
| Prostate cancer | Prostate cancer working group guidelines | CT, MRI, [18F]FDG-PET, X-ray, bone scintigraphy | Scher et al., 2016 84 |
| Hepatocellular carcinoma (HCC) | Modified RECIST (mRECIST) for HCC | Triphasic (pre-contrast, arterial, venous) CT or MRI | Llovet and Lencioni, 2020 85 |
| Malignant plueral mesothelioma | mRECIST v. 1.1 | CT | Armato and Nowak, 2018 86 |
| Central nervous system malignancies | |||
| High-grade glioma (HGG) and low-grade glioma (LGG) | RANO-HGG/LGG | Brain MRI - T1 pre-/post-contrast, T2/fluid attenuated inversion recovery (FLAIR) and optional DWI) |
Chuckwueke and Wen, 2019 87 |
| Brain metastases (BM) | RANO-BM | Brain MRI - T1 pre-/post-contrast, T2/fluid attenuated inversion recovery (FLAIR) and optional DWI) CT |
Lin et al., 2015 88 Camidge et al., 2018 89 |
| Leptomeningeal (LM) disease | RANO-LM | Brain MRI - T1 pre-/post-contrast, T2/fluid attenuated inversion recovery (FLAIR) and optional DWI) Spine MRI |
Chamberlain et al., 2017 90 Le Ruhn et al., 2019 91 Le Ruhn et al., 2022 92 |
| Neurofibromatosis type 1 (NF1) | Response evaluation in neurofibromatosis and schwannomatosis (REINS) | MRI-short tau inversion recovery (STIR). Volumetric measurment |
Dombi et al., 2013 93 |
| Paediatric neuro-oncology | International neuroblastoma response criteria (INRC) Response assesement in paediatric neuro-oncology (RAPNO) |
MRI—T1, axial T2 FLAIR, DWI. Apparent diffusion coefficient (ADC) measurement |
Erker et al., 2020 94 Park et al., 2017 95 |
| Hematological malignancies | |||
| Acute myeloid leukaemia (AML) | Cheson | X-ray, CT, MRI, PET | Cheson et al., 2003 96 |
| Chronic lymphocytic leukaemia (CLL) | International workshop on CLL (iwCLL) | CT | Hallek et al., 2018 97 |
| Hodgkin & non-Hodgkin’s Lymphoma | Lugano International Working Group consensus response evaluation criteria in lymphoma RECIL 2017 PINTaD Response Criteria in Lymphoma Working Group (PRoLoG) |
[18F]FDG-PET, CT | Cheson et al., 2014 98 Younes et al., 2017 99 Ricard et al., 2023 100,101 |
| Multiple myeloma | International myeloma working group (IMWG) | [18F]FDG-PET, CT, MRI | Kumar et al., 2016 102 |
PET, positron emission tomography.
Included are the specific imaging methods incorporated.